Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, 11829, Egypt.
Department of NE.UROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, 50019, Sesto Fiorentino, Firenze, Italy; Department of NEUROFARBA - Pharmaceutical and Nutraceutical Section, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Firenze, Via U. Schiff 6, 50019, Sesto Fiorentino, Firenze, Italy.
Eur J Med Chem. 2021 Jan 1;209:112897. doi: 10.1016/j.ejmech.2020.112897. Epub 2020 Oct 1.
In this study, diverse series of coumarin derivatives were developed as potential carbonic anhydrase inhibitors (CAIs). A "tail" approach was adopted by selecting the coumarin motif as a tail that is connected to the ZBG benzenesulfonamide moiety via a hydrazine (4a,b) or hydrazide (5a,b) linker. Thereafter, an aryl sulfone tail was incorporated to afford the dual tailed coumarin-sulfonamide arylsulfonehydrazones (13a-d) and hydrazides (14a,b). Then, the ZBG were removed from compounds 13 and 14 to furnish coumarin arylsulfonehydrazones (11a-d) and hydrazides (12a,b). Coumarin-sulfonamides 4 and 5 emerged as non-selective CAIs as they displayed good inhibitory activities toward all the examined CA isozymes (I, II, IX and XII) in the nanomolar ranges. Interestingly, the "dual-tail" approach (compounds 13 and 14) succeeded in achieving a good activity and selectivity toward CA IX/XII over the physiologically dominant CA I/II. In particular, compounds 13d and 14a were the most selective coumarin-sulfonamide counterparts. Concerning non-sulfonamide coumarin derivatives, coumarins 8 exhibited excellent activity and selectivity profiles against the target hCA IX/XII, whereas, coumarins 11 and 12 reported excellent selectivity profile, but they barely inhibited hCA IX/XII with Ks spanning in the micromolar ranges. Furthermore, molecular modelling studies were applied to get a deep focus about the feasible affinities and binding interactions for target coumarin-sulfonamides 4, 5, 13 and 14 with the active site for CA II, IX and XII isoforms.
在这项研究中,开发了多种香豆素衍生物作为潜在的碳酸酐酶抑制剂 (CAI)。采用“尾巴”方法,选择香豆素作为尾巴,通过肼 (4a,b) 或酰肼 (5a,b) 连接子连接到 ZBG 苯磺酰胺部分。此后,引入芳基砜尾巴,得到双尾香豆素-磺酰胺芳基砜腙 (13a-d) 和酰肼 (14a,b)。然后,从化合物 13 和 14 中去除 ZBG,得到香豆素芳基砜腙 (11a-d) 和酰肼 (12a,b)。香豆素-磺酰胺 4 和 5 作为非选择性 CAI 出现,因为它们在纳摩尔范围内对所有检查的 CA 同工酶 (I、II、IX 和 XII) 显示出良好的抑制活性。有趣的是,“双尾”方法 (化合物 13 和 14) 成功地实现了对 CA IX/XII 的良好活性和选择性,而生理上占主导地位的 CA I/II。特别是,化合物 13d 和 14a 是最具选择性的香豆素-磺酰胺对应物。关于非磺酰胺香豆素衍生物,香豆素 8 对靶标 hCA IX/XII 表现出优异的活性和选择性谱,而香豆素 11 和 12 报道了优异的选择性谱,但它们对 hCA IX/XII 的抑制作用几乎没有,Ks 跨越微摩尔范围。此外,还应用了分子建模研究来深入了解目标香豆素-磺酰胺 4、5、13 和 14 与 CA II、IX 和 XII 同工酶的活性位点的可行亲和力和结合相互作用。